Important Information Approved Uses INGREZZA® (valbenazine) capsules or INGREZZA® SPRINKLE (valbenazine) capsules are prescription medicines used to treat adults with: movements in the ...

Ingrezza (valbenazine) is a prescription drug that’s used to treat certain movement disorders. Ingrezza comes as a capsule that you swallow. Specifically, Ingrezza is used to treat these ...

About INGREZZA ® (valbenazine) Capsules and INGREZZA ® SPRINKLE (valbenazine) Capsules INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food ...

Do not take INGREZZA or INGREZZA SPRINKLE if you: are allergic to valbenazine, or any of the ingredients in INGREZZA or INGREZZA SPRINKLE. INGREZZA or INGREZZA SPRINKLE can cause serious side ...

Ingrezza (valbenazine) is a prescription drug used to treat involuntary movements caused by certain conditions. Ingrezza’s cost may depend on factors such as your dosage, whether you have health ...

Ingrezza (valbenazine) is a brand-name oral capsule prescribed for tardive dyskinesia and Huntington’s chorea. The cost of the drug with and without insurance can depend on several factors.

Do not take INGREZZA or INGREZZA SPRINKLE if you: are allergic to valbenazine, or any of the ingredients in INGREZZA or INGREZZA SPRINKLE. INGREZZA or INGREZZA SPRINKLE can cause serious side ...

Do not take INGREZZA or INGREZZA SPRINKLE if you: are allergic to valbenazine, or any of the ingredients in INGREZZA or INGREZZA SPRINKLE. INGREZZA or INGREZZA SPRINKLE can cause serious ...

presented data from the long-term KINECT ®-4 study demonstrating tardive dyskinesia remission in nearly 60% of participants at Week 48 with once-daily INGREZZA ® (valbenazine) capsules treatment.

presented data from the KINECT ®-HD study showcasing significant improvements in chorea across body regions with once-daily INGREZZA ® (valbenazine) capsules in adults with Huntington's disease.

About INGREZZA® (valbenazine) Capsules and INGREZZA® SPRINKLE (valbenazine) Capsules INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S.